1Hsu SC, Hung MC. Characterization of a novel tripartite nuclear localization sequence in the EGFR family [J]. J Biol Chem, 2007, 282(14): 10432-10440.
2Milanezi F, Carvalho S, Schnfitt FC. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy [J]. Expe Rev Mol Diagu, 2008, 8(4): 417.
3Niemiec JA, Adamczyk A, Maecki K, et al. Relationships between immunophenotype, Ki-67 index, microvascular density, Ep-CAM/ P-cadherin, and MMP-2 expression in early-stage invasive duetal breast cancer [J]. Appl [Epub ahead of print] Mol Morpho12012 Apr 23.
4Erdem O, Dursun A, Cosktm U, et al. the prognostic value of p53 and cerbB-2 expression, proliferative activity and angiogenesis in nodeegative breast cancer [J]. Tumor, 2005, 91(1): 46-52.
5Rivas MA, Tkach M, Beguelin W, et al. Transactivation of ErbB- 2 induced by tumor necrosis factor alpha promotes NF-kappaB activation and breast cancer cell proliferation [J]. Breast Cancer Res Treat, 2010, 122(1): 111-124.
6Yu HG, Ai YW, Yu LL, et al. Phosphoinositide3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death [J]. Int J Cancer, 2007, 122(2): 433-443.
7Brewer GJ. Copper lowering therapy with tetrathiomolybdate as anantiangiogenic strategy in cancer [J]. Curr Cancer Drug Targets, 2005, 5(3): 195-202.
8Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2 positive advanced gastric or gastro- oesophageal junction cancer (TOGA): a phase 3, open-label, randomised controlled trial [J]. Lancet, 2010, 376(9742): 687-697.
10Verri E, Guglielmini P, Puntoni M, et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic siiflcance [J]. Clin Study, 2005, 68(2-3): 154-16l.
3Emens LA. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer [J]. Am J Ther, 2005, 12(3): 243-253.
4AGUS DB, BUNN PA JR, FRANKLIN W, et al. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer[J]. Semin Oncol, 2000, 27(6 Suppl 11): 53-63.
5GREENE FL, COMP TON CC, FRITZ A G, et al. MCC Cancer Staging. Atlas[M]. New York: Springer, 2006: 77-88.
6WOLFF AC, HAMMOND ME, SCHWARTZ JN, et al. American society of clinical oneology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer [J]. J Clin Oncol, 2007, 25(1): 118-145.
7LAUDADIO J, QUIGLEY DI, TUBBS R, et al. HER2 testing: a review of detection methodologies and their clinical performance [J]. Expert Rev Mol Diagn, 2007, 7(1): 53-64.
8DREILICH M, WANDERS A, BRATPSTROM D, et al. HER-2 overexpression (3+) in patients with squamous ceU esophageal carcinoma correlates with poorer survival[J]. Dis Esophagus, 2006, 19(4): 224-231.
9AKAMATSU M, MATSUMOTO T, OKA K. C-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 2003, 57(5): 1323-1327.
10SATO S, KAJIYAMA Y, SUGANO M. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein [J]. Int J Radiat Oncol Biol Phys, 2005, 61(1): 203-211.
